At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 187 enrolled
Drug / intervention
Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg +1 moredrug
Likely dose
Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Study to Evaluate the Safety and Tolerability of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Japanese Subjects With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg and Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 187 participants across 35 sites.
Detailed Summary
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionJan 2012
TodayJul 2026
First PostedAug 31, 2010
Enrollment StartAug 1, 2010
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.8 years ago
Interventions
Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcgdrug
Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcgdrug
Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks